Heart Failure Treatment in 2023: Is There a Place for Lipid Lowering Therapy?
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F23%3A00079465" target="_blank" >RIV/00159816:_____/23:00079465 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/23:00133673
Result on the web
<a href="https://link.springer.com/article/10.1007/s11883-023-01166-3" target="_blank" >https://link.springer.com/article/10.1007/s11883-023-01166-3</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s11883-023-01166-3" target="_blank" >10.1007/s11883-023-01166-3</a>
Alternative languages
Result language
angličtina
Original language name
Heart Failure Treatment in 2023: Is There a Place for Lipid Lowering Therapy?
Original language description
Purpose of ReviewAn evidence for lipid lowering therapy in heart failure is briefly summarized in this review.Recent FindingsHeart failure therapy is based on recent guidelines for diagnosis and treatment of acute and chronic heart failure. The question of the importance of hypolipidemic treatment in heart failure remains insufficiently answered. We still rely only on results of two randomized controlled trials that did not show significant benefit of statins on mortality in these patients. In contrast, some meta-analysis, prospective or retrospective cohorts, found some positive effects of this therapy. Recently, the role of inflammation and the possibility of its influence by hypolipidemics have been discussed. PCSK9 inhibitors, new lipid lowering drugs, are very effective in LDL-cholesterol lowering and atherosclerotic cardiovascular diseases prevention. The role of PCSK9 inhibitors in heart failure treatment is investigated.SummaryBased on current knowledge, hypolipidemics are not generally recommended in heart failure therapy, unless there is another indication for their use.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems
Result continuities
Project
<a href="/en/project/LX22NPO5104" target="_blank" >LX22NPO5104: National Institute for Research of Metabolic and Cardiovascular Diseases</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Current Atherosclerosis Reports
ISSN
1523-3804
e-ISSN
1534-6242
Volume of the periodical
25
Issue of the periodical within the volume
12
Country of publishing house
US - UNITED STATES
Number of pages
8
Pages from-to
957-964
UT code for WoS article
001118155800003
EID of the result in the Scopus database
—